Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Arthritis Research & Therapy

Figure 2

From: Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome

Figure 2

FACS analysis of leukocytes in lacrimal glands, spleen and blood. FACS analysis was performed on leukocytes from lacrimal-glands, spleen and in peripheral blood taken from NOD mice after treatment from 10 to 20 weeks with either MOPC-21 control protein (n = 7 mice) or LTBR-Ig (n = 8 mice), as indicated. Gating for marginal zone B-cells or MZB (B220+/CD23-int/CD21-hi) is depicted for spleen cells (a) with the MZB region indicated (red circle, third dot-plot). Treatment with LTBR-Ig reduced MZB in spleen but not lacrimal glands (b), reduced the percent of B-cells approximately 4-fold, whereas the percentage of B-cells in peripheral blood increased (c), reduced the B-cell to T-cell ratio in lacrimal glands (d) and reduced the percentage of CD11c cells among non-T non-B-cells (e). Similar experiments (treatment 8 - 16 weeks) were performed at least four times. LTBR-Ig; lymphotoxin-beta receptor-mouse immunoglobulin (Fc) chimeric inhibitor; MZB, marginal zone B-cell; NOD, non-obese diabetic.

Back to article page